One pill to treat heart failure? new study tests simpler approach

NCT ID NCT04633005

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a single daily pill containing three heart failure drugs could help people with reduced ejection fraction, especially those with low income or from minority groups. 212 adults took either the polypill or standard separate medications. The goal was to see if the polypill made it easier to stick with treatment and improve heart function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Polypill (metoprolol succinate, empagliflozin, spironolactone)
What this could lead to
If successful, this could offer a simpler, cheaper way to manage heart failure, especially for low-income and minority patients.
What could go wrong
This is a small, early-phase trial (212 people) testing feasibility, not yet proven to improve outcomes. The polypill may not suit everyone or have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75209, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.